K

Knotus Co Ltd
KOSDAQ:278650

Watchlist Manager
Knotus Co Ltd
KOSDAQ:278650
Watchlist
Price: 2 160 KRW Market Closed
Market Cap: 181.9B KRW
Have any thoughts about
Knotus Co Ltd?
Write Note

Knotus Co Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Knotus Co Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
K
Knotus Co Ltd
KOSDAQ:278650
Current Portion of Long-Term Debt
â‚©56.4B
CAGR 3-Years
148%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Current Portion of Long-Term Debt
â‚©822.8B
CAGR 3-Years
356%
CAGR 5-Years
25%
CAGR 10-Years
N/A
S
ST Pharm Co Ltd
KOSDAQ:237690
Current Portion of Long-Term Debt
â‚©9.4B
CAGR 3-Years
157%
CAGR 5-Years
105%
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Current Portion of Long-Term Debt
â‚©1.1B
CAGR 3-Years
32%
CAGR 5-Years
22%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Current Portion of Long-Term Debt
â‚©268.6m
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Current Portion of Long-Term Debt
â‚©28.6B
CAGR 3-Years
323%
CAGR 5-Years
149%
CAGR 10-Years
N/A
No Stocks Found

Knotus Co Ltd
Glance View

Market Cap
181.9B KRW
Industry
Life Sciences Tools & Services

KNOTUS Co. Ltd. engages in the provision of clinical research services. The company is headquartered in Incheon, Incheon. The company went IPO on 2019-11-27. is a Korea-based company principally engaged in the nonclinical experiment business. Along with subsidiaries, the Company operates its business through three segments. The Nonclinical Contract Research Organization (CRO) Business segment conducts nonclinical experiments on new developed substances such as new drugs, and tests the efficacy and pharmacodynamics of the substances. This segment also provides services including new drug development related equipment, software and analysis of experimental results. The Animal Laboratory Construction Business segment is engaged in the construction and design of animal laboratories and the supply of reagent consumables. The Pet Business segment is engaged in the development of animal medicines and the sale of pet supplies.

Intrinsic Value
2 258.02 KRW
Undervaluation 4%
Intrinsic Value
Price
K

See Also

What is Knotus Co Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
56.4B KRW

Based on the financial report for Dec 31, 2023, Knotus Co Ltd's Current Portion of Long-Term Debt amounts to 56.4B KRW.

What is Knotus Co Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
148%

Over the last year, the Current Portion of Long-Term Debt growth was 1 458%. The average annual Current Portion of Long-Term Debt growth rates for Knotus Co Ltd have been 148% over the past three years .

Back to Top